These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9484774)

  • 41. Regulation of the MET oncogene: molecular mechanisms.
    Zhang J; Babic A
    Carcinogenesis; 2016 Apr; 37(4):345-55. PubMed ID: 26905592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning.
    Nosi V; Luca A; Milan M; Arigoni M; Benvenuti S; Cacchiarelli D; Cesana M; Riccardo S; Di Filippo L; Cordero F; Beccuti M; Comoglio PM; Calogero RA
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infrequent mutations of the MET gene in sporadic breast tumours.
    Bièche I; Champème MH; Lidereau R
    Int J Cancer; 1999 Sep; 82(6):908-10. PubMed ID: 10446461
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?
    Yap TA; Popat S
    J Thorac Oncol; 2017 Jan; 12(1):12-14. PubMed ID: 27988098
    [No Abstract]   [Full Text] [Related]  

  • 45. Tuning of alternative splicing--switch from proto-oncogene to tumor suppressor.
    Shchelkunova A; Ermolinsky B; Boyle M; Mendez I; Lehker M; Martirosyan KS; Kazansky AV
    Int J Biol Sci; 2013; 9(1):45-54. PubMed ID: 23289016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.
    Tsai JM; Hata AN; Lennerz JK
    Oncologist; 2021 Dec; 26(12):e2297-e2301. PubMed ID: 34347347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.
    Pilotto S; Gkountakos A; Carbognin L; Scarpa A; Tortora G; Bria E
    Ann Transl Med; 2017 Jan; 5(1):2. PubMed ID: 28164087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From Oncogene Interference to Neutrophil Immune Modulation.
    Bronte V
    Immunity; 2017 Oct; 47(4):613-615. PubMed ID: 29045894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties.
    Jumbe SL; Porazinski SR; Oltean S; Mansell JP; Vahabi B; Wilson ID; Ladomery MR
    Transl Oncol; 2019 Jan; 12(1):134-142. PubMed ID: 30296658
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Durham M; Vadde S; Brooks AN
    MicroPubl Biol; 2023; 2023():. PubMed ID: 37829573
    [No Abstract]   [Full Text] [Related]  

  • 51. Correction: Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping.
    Cancer Discov; 2016 Mar; 6(3):330. PubMed ID: 26896094
    [No Abstract]   [Full Text] [Related]  

  • 52. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.
    Bersani F; Picca F; Morena D; Righi L; Napoli F; Russo M; Oddo D; Rospo G; Negrino C; Castella B; Volante M; Listì A; Zambelli V; Benso F; Tabbò F; Bironzo P; Monteleone E; Poli V; Pietrantonio F; Di Nicolantonio F; Bardelli A; Ponzetto C; Novello S; Scagliotti GV; Taulli R
    J Exp Clin Cancer Res; 2023 May; 42(1):120. PubMed ID: 37170152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.
    Ayoub NM; Ibrahim DR; Alkhalifa AE
    Med Oncol; 2021 Oct; 38(12):143. PubMed ID: 34665336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma.
    Wang Q; Yu X; Li Q; Qin L; Tan S; Zeng X; Qiu X; Tang B; Jin J; Liao W; Qiu M; Tan L; He G; Li X; He S; Yu H
    Oncotarget; 2016 Nov; 7(48):79365-79371. PubMed ID: 27813498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiplexed, targeted profiling of single-cell proteomes and transcriptomes in a single reaction.
    Genshaft AS; Li S; Gallant CJ; Darmanis S; Prakadan SM; Ziegler CG; Lundberg M; Fredriksson S; Hong J; Regev A; Livak KJ; Landegren U; Shalek AK
    Genome Biol; 2016 Sep; 17(1):188. PubMed ID: 27640647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel isoform of met receptor tyrosine kinase blocks hepatocyte growth factor/Met signaling and stimulates skeletal muscle cell differentiation.
    Park M; Lee BS; Jeon SH; Nam HJ; Lee G; Kim CH; Cho H; Lee JH
    J Biol Chem; 2015 Jan; 290(3):1804-17. PubMed ID: 25471370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MET and autism susceptibility: family and case-control studies.
    Sousa I; Clark TG; Toma C; Kobayashi K; Choma M; Holt R; Sykes NH; Lamb JA; Bailey AJ; Battaglia A; Maestrini E; Monaco AP;
    Eur J Hum Genet; 2009 Jun; 17(6):749-58. PubMed ID: 19002214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pushing the limits of the scanning mechanism for initiation of translation.
    Kozak M
    Gene; 2002 Oct; 299(1-2):1-34. PubMed ID: 12459250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intron-exon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon.
    Lin JC; Naujokas M; Zhu H; Nolet S; Park M
    Oncogene; 1998 Feb; 16(7):833-42. PubMed ID: 9484774
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isoforms of the met receptor tyrosine kinase.
    Rodrigues GA; Park M
    EXS; 1993; 65():167-79. PubMed ID: 8380736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.